Thyroid protection in sickle cell anemia treatment
OwnerOji Agbaiinventor
Life of this patent
Estimating the term…
Abstract
In a method of providing anti-sickling of red blood cells in sickle cell anemia patients without hemolyzing the cells comprising, administering in a pharmaceutically acceptable vehicle an anti-sickling, non-hemolyzing amount of thiocyanate selected from the group consisting of alkali metal salts and an ammonium salt until the Hbss relative solubility ratio is at least 1.200 in the deoxygenated hemoglobin-S, the improvement of protecting the thyroid gland in the event of thiocyanate overdose, comprising administering along with the thiocyanate in the pharmaceutically acceptable vehicle, iodine in an amount sufficient to prevent thiocyanate overdose.
Claims12
In a method of providing anti-sickling of red blood cells in sickle cell anemia patients without hemolyzing the cells comprising, administering in a pharmaceutically acceptable vehicle an anti-sickling, non-hemolyzing amount of thiocyanate selected from the group consisting of alkali metal salts and an ammonium salt until the Hbss relative solubility ratio is at least 1.200 in the deoxygenated hemoglobin-S, the improvement of protecting the thyroid gland in the event of thiocyanate overdose, comprising administering along with said thiocyanate in said pharmaceutically acceptable vehicle iodine in an amount sufficient to prevent thiocyanate overdose.
The method of clam 1, wherein said iodine is potassium iodine.
The method of clam 8, wherein the amount of potassium iodine is in the amount of 2.86 ug/per kg of body weight.
In a pharmaceutically acceptable vehicle containing an anti-sickling, non-hemolyzing amount of thiocyanate selected from the group consisting of alkalai metal salts and an ammonium salt, the inclusion of iodine in an amount sufficient to prevent thiocyanate overdose to the thyroid gland.
Dependencies are inferred from the claim text.